NCT05535647尚未招募2 期
Second Line Therapy With Regorafenib and HAIC Compared to FOLFOX for Advanced Intrahepatic Cholangiocarcinoma
Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年9月25日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
This is a prospective, Two-arm, comparative, randomized, controlled phase II trial, to explore the efficacy and safety of Regorafenib and HAIC vs. FOLFOX as Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma.
详细描述
Currently, complete surgical resection represents the only potentially curative treatment option for cholangiocarcinoma (CCA, including intrahepatic, hilar and distal CCA) and gallbladder carcinoma (GBCA). However,only less than 25% of patients are resectable at diagnosis and, even in this subset of patients, relapse rate is high.
Cisplatin and gemcitabine combination was identified as the standard first-line chemotherapy, yielding a median progression free survival (PFS) and median OS of 8.5 and 11.7 months, respectively. FOLFOX was the standard second-line chemotherapy. But the benefit of FOLFOX was limited.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated IRB/IEC-approved Informed Consent.
- •Cytological or histological diagnosis of locally advanced or metastatic adenocarcinoma of the Intrahepatic Cholangiocarcinoma.
- •Disease progressing after first-line chemotherapy with gemcitabine and platinum analogs (only one prior systemic therapy allowed).
- •Age 18-75 years
- •Karnofsky Performance Status > 50%
- •Estimated life expectancy of at least 3 months.
- •Negative pregnancy test (if female in reproductive years).
- •Adequate bone marrow, liver and kidney function: leukocyte > 3500/mm3; absolute neutrophil count (ANC) > 1500/mm3; platelet count > 100000/mm3; hemoglobin > 10 g/dl; creatinine < 1.5 mg/dL; total bilirubin ≤ 1.5 x upper limit of normal range (ULN); SGOT e SGPT ≤ 2.5 ULN
- •At the time of start of treatment, at least 2 weeks must have elapsed since completion of prior chemotherapy, minor surgery and radiotherapy (provided that no more than 25% of bone marrow reserve has been irradiated).
- •Resolution of all acute toxic effects of any prior chemotherapy, surgery or radiotherapy to NCI CTC (Version 4.03) grade ≤ 1 for hematologic toxicities and ≤ 2 for non hematologic toxicities, with the exception of alopecia.
- •Able and willing to comply with scheduled visits, therapy plans, and laboratory tests required in this protocol.
排除标准
- •History of cardiac disease
- •Ongoing infection > Grade 2 according to NCI-CTCAE version 4.
- •Hepatitis B is allowed if no active replication (defined as abnormal ALT >2xULN associated with HBV DNA >20,000 IU/mL) is present
- •Severe co-morbid illness and/or active infections including active hepatitis C and human immunodeficiency virus (HIV) infection
- •History of interstitial lung disease (ILD).
- •Any cancer curatively treated < 3 years prior to study entry, except cervical carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors (Staging: Ta, Tis and T1).
- •Renal failure requiring hemo- or peritoneal dialysis.
- •Clinically significant GI bleeding (CTCAE 4.03 grade 3 or higher) within 30 days prior to start of screening
- •Thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks) within 6 months prior to start of screening.
- •History of organ allograft, cornea transplantation will be allowed
- •Active CNS metastases not controllable with radiotherapy or corticosteroids Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk factor for RVO or CSR.
- •Known history of hypersensitivity to study drugs
- •Non-healing wound, ulcer, or bone fracture.
- •Patients with seizure disorder requiring medication.
- •Acute steroid therapy or taper for any purpose (chronic steroid therapy is acceptable provided that the dose is stable for 1 month before start of screening and thereafter).
- •Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
- •Pregnant or lactating women. Women of childbearing potential not employing adequate contraception. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to start of study treatment and a negative result must be documented before first dose of study drug.
研究组 & 干预措施
Regorafenib and HAIC
Experimental
Regorafenib HAIC with FOLFOX
干预措施: Regorafenib and HAIC (Drug)
FOLFOX
Active Comparator
FOLFOX
干预措施: FOLFOX (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: 12month
the rate of complete response and partial response among all evaluable patients
次要结局
- Disease control rate (DCR)(12 months)
- Progression-free Survival (PFS)(12 months)
- Overall Survival (OS)(24 months)
- Adverse events (AE)(24 months)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Regorafenib Plus Gemcitabine in Metastatic Pancreatic CancerMetastatic Pancreatic AdenocarcinomaNCT02383433Case Comprehensive Cancer Center2
已完成
2 期
Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal CancerColo-rectal CancerMetastatic CancerNCT04534218Centre Hospitalier Universitaire de Besancon49
Unknown
2 期
Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）Hepatocellular CarcinomaNCT04806243Nanfang Hospital, Southern Medical University69
招募中
不适用
Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRCColorectal Cancer MetastaticNCT06456515The First People's Hospital of Changzhou30
终止
2 期
Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric CancerGastric CancerNCT00595985Fudan University5